← Leaderboards
Bethany Mundy-Bosse
Ohio State University
$1,809,973
Attributed
$3,059,426
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $514.4K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,059,426 · 2
By mechanism
R01$2,498,906 · 1
K22$560,520 · 1
Top collaborators
- Christopher C. Oakes5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Anna E Vilgelm$2,524,271
- Christopher C. Oakes$2,619,311
- Pearlly Yan$744,830
- Michael R Grever$17,739,693
- Matthew Lordo$193,322
Others in their field
Other Emerging Leaders on “Natural Immunity”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$149,420,148
- Wilton B Williams · Duke University$17,455,745
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,459,738
- Kevin Urdahl · Seattle Children'S Hospital$13,980,154
- Vanessa Rivera-Amill · Ponce School Of Medicine$12,587,042
- Paul John Norman · University Of Colorado Denver$11,056,774
Research focus
Natural ImmunityMolecularImmune EvasionInnate Immune SystemLeukemiaMalignant NeoplasmsHomeostasisImmuneCytokineImmunologic SurveillanceDefectCancer CellDetectionDisease ProgressionAryl Hydrocarbon ReceptorEnvironmentAryl Hydrocarbon Receptor LigandCell PhysiologyCellsAutomobile DrivingAdaptive Immune ResponseImmune SystemAcute Myelocytic LeukemiaNatural Killer Cells
Grant awards (8)
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia$506,825
R01 · FY2025 · CA · contact PI
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia$481,484
R01 · FY2024 · CA · contact PI
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia$496,689
R01 · FY2023 · CA · contact PI
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia$499,474
R01 · FY2022 · CA · contact PI
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia$514,434
R01 · FY2021 · CA · contact PI
The Role of miR-29b in NK cell Development in Acute Myeloid Leukemia$186,840
K22 · FY2020 · CA · contact PI
The Role of miR-29b in NK cell Development in Acute Myeloid Leukemia$186,840
K22 · FY2019 · CA · contact PI
The Role of miR-29b in NK cell Development in Acute Myeloid Leukemia$186,840
K22 · FY2018 · CA · contact PI